A position statement of the Slovenian endocrine society on the management of glucocorticoid-induced osteoporosis

  • Tomaž Kocjan Department of Endocrinology, Diabetes and Metabolic Diseases, UMC Ljubljana
  • Mojca Jensterle Sever Department of Endocrinology, Diabetes and Metabolic Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana
  • Janez Preželj Department of Endocrinology, Diabetes and Metabolic Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana
Keywords: bisphosphonates, glucocorticoids, osteoporotic fractures, teriparatide, treatment

Abstract

Zdravljenje z glukokortikoidi je najpogostejši vzrok sekundarne osteoporoze. Za glukokortikoidno osteoporozo je značilno zelo hitro zmanjšanje mineralne kostne gostote z naglim zvišanjem tveganja za osteoporozne zlome, zato priporočamo ob uvedbi glukokortikoida oceniti bolnikovo tveganje za zlom in mu svetovati glede zdravega načina življenja ter vnosa kalcija, vitamina D in beljakovin. Če je indicirano, uvedemo tudi eno od zdravil za zaščito kosti, s čimer povečamo mineralno kostno gostoto in zmanjšamo tveganje za zlome vretenc. Večinoma predpišemo bisfosfonate, bolj ogroženim bolnikom, ki so zlome že utrpeli, lahko tudi teriparatid.

Downloads

Download data is not yet available.

References

Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011 Jul;365(1):62–70. https://doi.org/10.1056/NEJMcp1012926 PMID:21732837

Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int. 2005 Jun;16(6):581–9. https://doi.org/10.1007/s00198-004-1780-5 PMID:15616758

Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, et al.; Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012 Sep;23(9):2257–76. https://doi.org/10.1007/s00198-012-1958-1 PMID:22434203

Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1515–26. https://doi.org/10.1002/acr.20295 PMID:20662044

Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1095–110. https://doi.org/10.1002/acr.23279 PMID:28585410

Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol. 2015 Feb;11(2):98–109. https://doi.org/10.1038/nrrheum.2014.188 PMID:25385412

Hansen KE, Wilson HA, Zapalowski C, Fink HA, Minisola S, Adler RA. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res. 2011 Sep;26(9):1989–96. https://doi.org/10.1002/jbmr.362 PMID:21721042

Díez-Pérez A, Hooven FH, Adachi JD, Adami S, Anderson FA, Boonen S, et al.; The Global Longitudinal Study of Osteoporosis in Women (GLOW). Regional differences in treatment for osteoporosis. Bone. 2011 Sep;49(3):493–8. https://doi.org/10.1016/j.bone.2011.05.007 PMID:21605715

Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2016 May;27(5):1709–18. https://doi.org/10.1007/s00198-015-3455-9 PMID:26694595

Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int. 2005 Dec;16(12):2168–74. https://doi.org/10.1007/s00198-005-2016-z PMID:16142501

Mirza F, Canalis E. Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015 Sep;173(3):R131–51. https://doi.org/10.1530/EJE-15-0118 PMID:25971649

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008 Apr;19(4):385–97. https://doi.org/10.1007/s00198-007-0543-5 PMID:18292978

Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23–57. https://doi.org/10.1007/s00198-012-2074-y PMID:23079689

Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, et al.; Task Force of the FRAX Initiative. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011 Sep;22(9):2395–411. https://doi.org/10.1007/s00198-011-1713-z PMID:21779818

Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011 Mar;22(3):809–16. https://doi.org/10.1007/s00198-010-1524-7 PMID:21229233

Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD Open. 2015 Apr;1(1):e000014. https://doi.org/10.1136/rmdopen-2014-000014 PMID:26509049

Tatsuno I, Sugiyama T, Suzuki S, Yoshida T, Tanaka T, Sueishi M, et al. Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab. 2009 May;94(5):1671–7. https://doi.org/10.1210/jc.2008-1578 PMID:19258412

Genant HK, Engelke K, Fuerst T, Glüer CC, Grampp S, Harris ST, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res. 1996 Jun;11(6):707–30. https://doi.org/10.1002/jbmr.5650110602 PMID:8725168

Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003 Nov;48(11):3224–9. https://doi.org/10.1002/art.11283 PMID:14613287

American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001 Jul;44(7):1496–503. https://doi.org/10.1002/1529-0131(200107)44:73.0.CO;2-5 PMID:11465699

Ulivieri FM, Silva BC, Sardanelli F, Hans D, Bilezikian JP, Caudarella R. Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine. 2014 Nov;47(2):435–48. https://doi.org/10.1007/s12020-014-0280-4 PMID:24853880

Geusens PP, de Nijs RN, Lems WF, Laan RF, Struijs A, van Staa TP, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004 Mar;63(3):324–5. https://doi.org/10.1136/ard.2003.008060 PMID:14962971

Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al.; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010 Nov;182(17):1864–73. https://doi.org/10.1503/cmaj.100771 PMID:20940232

Rizzoli R. Nutrition: its role in bone health. Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):813–29. https://doi.org/10.1016/j.beem.2008.08.005 PMID:19028358

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911–30. https://doi.org/10.1210/jc.2011-0385 PMID:21646368

Kocjan T, Preželj J, Pfeifer M, Sever MJ, Čokolič M, Zavratnik A. Guidelines for the detection and treatment of osteoporosis. Zdr Vestn. 2013;82:207–17.

Saag K, Wagman R, Geusens P, Adachi J, Messina O, Emkey R, et al., editors. Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized. Double-Blind, Active-Controlled Study. Annals of the Rheumatic Diseases; 2017.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007 Nov;357(20):2028–39. https://doi.org/10.1056/NEJMoa071408 PMID:18003959

McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017 May;28(5):1723–32. https://doi.org/10.1007/s00198-017-3919-1 PMID:28144701

Published
2018-10-28
How to Cite
1.
Kocjan T, Jensterle Sever M, Preželj J. A position statement of the Slovenian endocrine society on the management of glucocorticoid-induced osteoporosis. SlovMedJour [Internet]. 28Oct.2018 [cited 9Dec.2018];87(9-10):453-60. Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/2637
Section
Professional Article